The BBI Group (BBI) today announced it has developed in collaboration with the Defence Science and Technology Laboratory (Dstl) and licensed, through technology transfer company Ploughshare Innovations, a rapid test for Ebola. The assay, which is in the process of being verified to allow EUA submission, will be used to test patients suspected of Ebola infection to screen and potentially help with how they are subsequently managed. The test, utilising lateral flow technology, can provide a result in approximately 20 minutes.
BBI is a England-based medical device firm that produces critical reagents, immunoassay and lateral flow products for diagnostics and life sciences industries.